Pharma Deals Review, Vol 2007, No 79 (2007)

Font Size:  Small  Medium  Large

R&D in the Alzheimer’s Field

Business Review Editor

Abstract


GlaxoSmithKline and EPIX Pharmaceuticals entered into a worldwide alliance to discover, develop and market novel medicines targeting four G-protein coupled receptors (GPCRs) for treating Alzheimer’s disease. The deal could worth US$1.235 B.

Full Text: pdf

Add comment

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.